Physician profile
Bernard D Stokes
NPI 1205830080
$13,537.42
in general payments reported to CMS, 2019-2025
32 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $784 · 2021: $2,417 · 2022: $2,439 · 2023: $2,208 · 2024: $3,094 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,118 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,118.29 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,750.57 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $1,914.77 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,257.30 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $698.18 | 2019-2025 | Xifaxan, Plenvu, Relistor |
| Pfizer INC. | $583.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $454.53 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $297.65 | 2019-2025 | |
| Celgene Corporation | $283.53 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $242.47 | 2023-2025 | Omvoh |
| Redhill Biopharma INC. | $228.70 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $220.36 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $198.58 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $194.25 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $160.73 | 2021-2024 | Dificid |
| Genzyme Corporation | $121.79 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $116.55 | 2020-2023 | Rebyota |
| Janssen Scientific Affairs, LLC | $109.66 | 2022 | |
| Amgen INC. | $107.64 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $101.77 | 2022 | |
| Evoke Pharma, INC. | $87.91 | 2021-2024 | |
| Ardelyx, INC. | $82.58 | 2022-2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $80.51 | 2020-2024 | Linzess |
| Organon LLC | $61.15 | 2022-2025 | Hadlima |
| Qol Medical, LLC | $50.73 | 2022-2023 | Sucraid |
| Braintree Laboratories, INC. | $35.21 | 2020-2022 | |
| Madrigal Pharmaceuticals | $19.49 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $17.80 | 2024 | Iqirvo |
| Celltrion USA INC. | $16.61 | 2025 | Vegzelma |
| Shire North American Group INC | $14.80 | 2019 | |
| Novo Nordisk INC | $14.46 | 2025 | Wegovy |
| Boston Scientific Corporation | $13.32 | 2024 | Cre Pro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$38,545.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.